Bionow | News

BioCap 2024: key themes from the investment panel by RSM UK

Dec 3rd 2024

At BioCap 2024, Graham Bond, RSM UK’s Co-Head of Life Sciences, chaired an IPO session featuring a panel of life sciences experts and investors. Below, Graham summarises key themes raised ...

What makes transfer pricing an important issue for growing life sciences busines...

Sep 30th 2024

Our tax experts explore the importance of transfer pricing for life sciences businesses as international expansion is often considered at an early stage in their lifecycle.

UK government must tap into and interconnect with investors to support NHS, says...

Jul 11th 2024

With the new Labour government pledging to 'build an NHS fit for the future', an injection of money, whilst welcome, will not be enough - it must be rolled out in a measured and integrated w...

Life Sciences: UK funding continues to come under pressure

Jun 21st 2024

Laragh Jeanroy and Graham Bond, co-heads of life sciences at RSM, comment on the challenges of the funding landscape, while private equity is under pressure to deploy capital and there is ca...

Upcoming R&D regime changes – what is the impact for Clinical Research Organis...

Jun 21st 2024

Clinical Research Organisations and contracting entities will be impacted by the upcoming R&D regime changes. Read our dedicated guidance.

Life sciences: how can you prepare for UK GAAP changes?

Feb 26th 2024

The FRC's decision to delay the effective date of future changes to UK GAAP presents a strategic window of opportunity for the UK life sciences industry. Find out how you can prepare.

How have recent R&D changes landed with UK life sciences?

Oct 13th 2023

Phil Melia, Corporate Tax Partner, and Max Stanyard, Innovation Reliefs Specialist, examine the impact of R&D regime changes for life sciences and biotech businesses in the UK

GenEthics: Considerations for biotech and healthcare

Oct 11th 2022

Academics and philosophers are hotly debating what the advances in genetics could mean for society – particularly when it comes to testing for predisposition to conditions like cancer and ...

RSM US Insight: Life sciences investments strong in US, but not record breaking ...

Apr 20th 2021

What’s in store for life sciences investing in 2021? Coming off a record high in 2020 and with many funds recently raised, fundraising will likely decline in 2021 to be in line with 2019's...

RSM Coronavirus Hub - Insights, advice and support

Apr 3rd 2020

The coronavirus pandemic is causing disruption and uncertainty across the globe and businesses are facing many challenges. As the Government continues to announce support and advice, we will...

News